Clinical Trials Logo

Bronchiolitis clinical trials

View clinical trials related to Bronchiolitis.

Filter by:

NCT ID: NCT04408534 Not yet recruiting - Bronchiolitis Clinical Trials

Bilevel Noninvasive Ventilation in Infants With Bronchiolitis Presenting With Apnea

Start date: December 1, 2020
Phase: N/A
Study type: Interventional

This physiological study aims to compare Bilevel Positive Airway Pressure and continuons positive airway pressure in infants with severe bronchiolitis presenting with apnea

NCT ID: NCT04168554 Not yet recruiting - Asthma Clinical Trials

Telemedicine in the Generals Practitioners Office

Start date: December 2019
Phase:
Study type: Observational

Pediatrician does physical examination through telemedicine and in real life to see whether the telemedicine consultation corresponds with the real life examination. Goal is to determine: 1. Check practical feasability 2. Check whether there are no great objections for a larger study (ie. in case telemedicine consultation is much more unreliable to do a physical examination a larger study is deemed unsafe)

NCT ID: NCT04144816 Not yet recruiting - Clinical trials for Respiratory Syncytial Virus Infections

Predictors of Respiratory Syncytial Virus (RSV) Hospitalizations in Infants

PRSVH
Start date: October 2019
Phase:
Study type: Observational

The VRS (Respiratory Syncytial Virus) study group in Lyon is a working that aims to understand, predict and prevent the burden of disease caused by human respiratory syncytial virus (RSV) infection in infants. Incidence of RSV-associated hospitalization in the first year of life was estimated at 14.5 (95% CI 13.4-15.6) per 1000 births in a cohort study in Lyon, France. Related direct medical annual costs were estimated for this cohort at 364,269€, mostly attributed to children born during the RSV season (231,959€) and children born premature (108,673€). This study will combine existing hospital specimens and databases to determine the respective role of socio demographic factors, clinical risk factors, level of cord specific antibody at birth, and virus characteristic in the Respiratory Syncytial Virus (RSV) Hospitalization outcome in Infants. Regarding the introduction of a new RSV vaccine and RSV-specific neutralizing antibodies, these data are of prime importance to guide future vaccine policies.

NCT ID: NCT04099082 Not yet recruiting - Clinical trials for Acute Respiratory Infection

Signature of the Host Response to a Respiratory Viral Infection, in the Prediction of Bronchiolitis Obliterans

ALLOPIV
Start date: March 15, 2020
Phase:
Study type: Observational

Bronchiolitis obliterans (BO) is the well-known manifestation of the chronic pulmonary graft-versus-host disease(GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT). The pathophysiology of BO is, however, poorly known. The available data strongly support the role of respiratory viruses, in particular paramyxoviruses (parainfluenzae virus (PIV), respiratory syncytial virus, metapneumovirus). It is likely that the alloimmune response triggered by the respiratory virus is inadequate and leads to the peribronchiolar fibrotic process. The objective is to analyze the kinetics of profiles of the blood and respiratory host responses resulting from a high or low parainfluenza respiratory infection, in order to evaluate if the occurrence of a BO is associated with a specific signature We will evaluate the predictive signature of a BO after a parainfluenza virus infection by characterizing the differences between the patients evolving and those not evolving to a BO at 2 months after the infection.

NCT ID: NCT04029636 Not yet recruiting - Clinical trials for Bronchiolitis Obliterans

Hyperpolarized 129Xe MRI for the Assessment of BOS With Late Onset LONIPC

BOS-MRI
Start date: August 2019
Phase:
Study type: Observational

The development of bronchiolitis obliterans syndrome (BOS) and other late onset non-infectious pulmonary complications (LONIPCs) following hematopoietic stem cell transplantation (HSCT) is associated with a significantly worse prognosis, high disease burden, and excessive health resource utilization. In this proposal, the investigators plan to examine and compare different diagnostic modalities which can provide detailed physiological and anatomical characterization of LONIPCs.

NCT ID: NCT03915197 Not yet recruiting - Asthma Clinical Trials

Acute Bronchiolitis in Infants and Allergic Asthma

Start date: May 2, 2019
Phase: N/A
Study type: Interventional

Predicting the risk of allergenic sensitizations and asthma development in the first year of life is difficult. Investigator decided to follow prospectively two cohorts of infants with acute bronchiolitis, hospitalized or treated at home, from the epidemic seasons of 2011-2012 and 2015-2017 to know their respiratory evolution, especially if they developed allergen sensitization and / or asthma.

NCT ID: NCT03880903 Not yet recruiting - Acute Bronchiolitis Clinical Trials

Hypertonic Saline Inhalation in Acute Bronchiolitis

Start date: July 20, 2020
Phase: Phase 4
Study type: Interventional

Acute bronchiolitis is a viral infection that occurs in children most commonly in the first 2 years of life and is characterized by respiratory symptoms, resulting in wheezing and/or crackles upon auscultation. It is usually a self limiting illness. However, this condition may be associated with several severe complications, such as apnea,respiratory failure, or secondary bacterial infection

NCT ID: NCT03619499 Not yet recruiting - Clinical trials for Non Invasive Ventilation

Non Invasive Ventilation in Bronchiolitis

Start date: March 1, 2019
Phase: N/A
Study type: Interventional

It is decided to perform a prospective study in a non-selected population of infants with bronchiolitis during one year ( October.2018 to October.2019) to study the characteristics, clinical course and outcome of the use of Non invasive ventilation in the management and compare the results with those treated with invasive ventilation to assess safety and efficacy and inform guideline construction.

NCT ID: NCT03436225 Not yet recruiting - Clinical trials for Bronchiolitis; Respiratory Syncytial Virus

Steroid Therapy in Acute Bronchiolitis A New Old Line of Therapy.

Start date: February 2019
Phase: Phase 1
Study type: Interventional

The aim of the present study is to evaluate the efficacy of steroid therapy and hospital stay in patients with acute bronchiolitis at assiut university children hospital.

NCT ID: NCT02585531 Not yet recruiting - Bronchiolitis Clinical Trials

Epinephrine, Dexamethasone and Hypertonic Saline in Bronchiolitis

Start date: November 2015
Phase: Phase 2
Study type: Interventional

Bronchiolitis is one of the main reasons for consultation in primary care and emergency services, as well as the leading cause of hospitalization for lower respiratory tract infection in children under two years. There is still no consensus on the medical management of the disease, in clinical practice there is wide variability in the treatment with inhaled drugs and / or oral bronchodilators, steroids, antihistamines despite the viral etiology of the disease, which results in increased morbidity and a major economic benefit for all health services. Several studies are in relation to the management of bronchiolitis, one of which was made during 2014 in the Naval Hospital of High Specialty which included 90 participants comparing 3 treatment. The treatments administered were: dexamethasone and epinephrine (Levogira) (ED), hypertonic saline 3% (SSH 3%)and saline 0.9% ( SS 0.9%), finding that the handling of ED and SSH 3% had lower rates of hospital admissions compared to the symptomatic management of SS 0.9%. Although the superiority of SSH3% and ED in relation to the use of SS 0.9% was demonstrated, it was not possible to establish difference statistically significant between them. Why it was considered necessary to continue the study focused on determining the difference in the effectiveness of ED and SSH 3%. Therefore, the purpose of this investigation is to determine whether there is a difference between the use of dexamethasone and epinephrine versus hypertonic saline (3%).